Literature DB >> 18173967

Which basal insulin should be used in patients with type 2 diabetes mellitus?

John N Clore1, Linda Thurby-Hay.   

Abstract

The initiation of insulin therapy is a significant event for patients with diabetes and the physicians who care for them. Reluctance to begin insulin is multifactorial, with major stumbling blocks being the perceived complexity of insulin and fear of hypoglycemia. Recent guidelines supporting earlier introduction of insulin to achieve glycemic goals in patients with type 2 diabetes mellitus will require that traditional approaches to insulin therapy be altered and a new paradigm be introduced into clinical practice. In particular, an understanding of the role of basal insulin in the regulation of glucose and the development of strategies to implement basal insulin therapy can provide a transition that is rational and highly effective in most patients. The strategy also offers a unique approach to diabetes education that permits a focused and patient-specific correction to glucose abnormalities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18173967     DOI: 10.1007/s11892-007-0057-8

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  28 in total

Review 1.  Evening insulin strategy.

Authors:  M C Riddle
Journal:  Diabetes Care       Date:  1990-06       Impact factor: 19.112

Review 2.  Patient empowerment: reflections on the challenge of fostering the adoption of a new paradigm.

Authors:  Robert M Anderson; Martha M Funnell
Journal:  Patient Educ Couns       Date:  2005-05

3.  Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.

Authors:  H Yki-Järvinen; L Ryysy; K Nikkilä; T Tulokas; R Vanamo; M Heikkilä
Journal:  Ann Intern Med       Date:  1999-03-02       Impact factor: 25.391

4.  Patient empowerment. Results of a randomized controlled trial.

Authors:  R M Anderson; M M Funnell; P M Butler; M S Arnold; J T Fitzgerald; C C Feste
Journal:  Diabetes Care       Date:  1995-07       Impact factor: 19.112

5.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

6.  Effect of fatty acids on glucose production and utilization in man.

Authors:  E Ferrannini; E J Barrett; S Bevilacqua; R A DeFronzo
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

7.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin.

Authors:  K Rebrin; G M Steil; L Getty; R N Bergman
Journal:  Diabetes       Date:  1995-09       Impact factor: 9.461

10.  Effects of acute insulin excess and deficiency on gluconeogenesis and glycogenolysis in type 1 diabetes.

Authors:  Guenther Boden; Peter Cheung; Carol Homko
Journal:  Diabetes       Date:  2003-01       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.